Trial Profile
A Pilot Study on the Efficicay and Safety of Pegylated Interferon, Ribavirin and Telaprevir in Recurrent Hepatitis C Virus (HCV) Infection in Orthotopic Liver Transplant (OLT) Recipients.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 23 Nov 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 10 May 2012 New trial record